News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abiomed (ABMD) Release: New Data Confirms Early Implantation of Impella 2.5 Prior to PCI Improves Survival in Shock Patients



11/11/2011 12:27:50 PM

DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new results from a multicenter retrospective study demonstrating that early initiation of support with ImpellaĀ® 2.5 prior to revascularization improves survival in emergent patients as compared to those receiving Impella 2.5 support after percutaneous coronary intervention (PCI). Specifically, the analysis demonstrated that shock patients that received Impella before revascularization had a higher survival rate (65% vs. 39%, p=0.007 respectively, N=119).

Read at BioSpace.com


comments powered by Disqus
Abiomed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES